Azitra Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company focused on precision dermatology. Recent disclosures cover proxy materials for annual and special stockholder meetings, shareholder voting procedures, board and governance matters, and meeting-status updates filed on Form 8-K.
Azitra's SEC reports also describe material agreements and capital-structure changes, including private placement securities, Series A preferred stock and Series B and Series C warrants. Other filings address furnished financial results, pipeline business updates, use of financing proceeds for research and development and working capital, and NYSE American continued-listing compliance matters tied to stockholders' equity standards.
Azitra, Inc. entered into a private placement with a single institutional investor, raising approximately $1.5 million in gross proceeds through common stock and warrant issuances priced at a premium to market in line with NYSE rules. The company is selling 535,759 shares of common stock, pre-funded warrants for up to 4,151,741 shares at an exercise price of $0.0001 per share, and common warrants to purchase up to 4,687,500 shares at an exercise price of $0.32. The common warrants become exercisable upon shareholder approval and expire five years after that approval, while the pre-funded warrants are immediately exercisable and do not expire until fully exercised. Azitra will use the proceeds for general corporate purposes and agreed to customary lock-up, participation, and registration rights, including filing a resale registration statement within 20 days and seeking effectiveness within 60–90 days.
L1 Capital Global Opportunities Master Fund, Ltd. filed an amended Schedule 13G/A for Azitra, Inc. (AZTR), reporting beneficial ownership of 273,497 shares of Common Stock, representing 2.6% of the class.
The filing states that the 273,497 shares include Common Stock underlying 273,497 warrants. The percentage is based on 10,204,938 shares outstanding as of November 11, 2025, as referenced from the issuer’s Form 10-Q. The holder reports sole voting and dispositive power over 273,497 shares and certifies the securities were not acquired to change or influence control. The date of the event is November 14, 2025.
Azitra, Inc. (AZTR) filed an 8-K and furnished a press release announcing financial results for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and incorporated by reference in this report solely for Item 2.02. The company notes the information is furnished, not filed, meaning it is not subject to Section 18 liabilities and is not incorporated into other filings under the Securities Act or Exchange Act by general reference.
Azitra, Inc. (AZTR) filed its Q3 2025 report, showing no revenue and a net loss of $2.8 million for the quarter. Operating expenses were $2.8 million (G&A $1.59 million; R&D $1.18 million). Year to date, the company reported a net loss of $8.7 million and used $8.3 million in operating cash.
Cash and cash equivalents were $1.4 million with stockholders’ equity of $2.3 million as of September 30, 2025. Shares outstanding were 5,604,938 as of September 30, 2025; the company reported 10,204,938 shares outstanding as of November 11, 2025. Azitra drew on a $20 million equity line of credit, issuing 7,955,823 shares and 795,579 warrants for gross proceeds of $6.0 million, with approximately $14.0 million remaining available as of November 12, 2025.
NYSE American issued a deficiency notice on October 1, 2025, citing stockholders’ equity below $4.0 million; Azitra submitted a compliance plan. Management disclosed substantial doubt about going concern due to the accumulated deficit of $66.3 million, ongoing losses, and limited working capital of $0.4 million. The company effected reverse stock splits in 2024 and 2025 and increased authorized common shares to support capital-raising.
Azitra, Inc. received a notice from NYSE American that it no longer meets the exchange’s listing standard requiring at least $4.0 million in stockholders’ equity for companies with losses in three of the four most recent fiscal years. As of June 30, 2025, Azitra reported stockholders’ equity of $2.2 million and losses in three of its four most recent fiscal years ended December 31, 2024.
The company has until October 31, 2025 to submit a plan to regain compliance by April 1, 2027. If the plan is accepted, Azitra will undergo periodic reviews, and failure to execute or regain compliance by that date may lead to delisting proceedings. The letter does not immediately affect the listing or trading of Azitra’s common stock and does not change its SEC reporting obligations.
Azitra Inc. states two offering scenarios and how net proceeds would fund operations under its current plan. If the company receives $8.95 million of net proceeds (based on gross proceeds of $10.0 million), management believes those proceeds, together with existing cash on hand, will satisfy its capital needs until October 2026. If the company receives $6.95 million of net proceeds (based on gross proceeds of $8.0 million), management believes those proceeds, without additional cash on hand, will satisfy its capital needs until September 2026. The filing discloses a historical net tangible book value per share as of June 30, 2025 of $0.48 and shows a pro forma net tangible book value per share increasing to $0.74 in one scenario and to $0.84 in another, with an indicated dilution of $0.14 per share to new investors.
Azitra, Inc. entered into a Modification Agreement with Alumni Capital LP that updates pricing terms under an existing equity purchase agreement for up to $20 million of common stock. The company can require Alumni Capital to buy shares in tranches of up to $750,000 each, or up to $4 million per purchase if both parties agree in writing. For each purchase, Azitra may choose between two pricing methods: either 90% of the lowest daily volume-weighted average price over a period of up to five business days after a purchase notice, or 97% of the lowest traded price from the date the purchase notice is delivered through the time Alumni Capital is ready to close. All other terms of the original April 24, 2025 purchase agreement remain in effect.
Alumni Capital LP, its general partner Alumni Capital GP LLC, and control person Ashkan Mapar filed a Schedule 13G reporting a deemed beneficial ownership of 2,605,586 shares of Azitra, Inc. common stock, representing 9.99% of the class. The reported position reflects shares the Fund may acquire under a Purchase Agreement and existing or to-be-issued Commitment Warrants, including a present right to acquire 849,700 shares on exercise of outstanding warrants. Ownership is subject to stated limits: a Warrant Ownership Limitation that caps ownership at 9.99% and a Purchase Agreement Ownership Limitation that currently caps purchases at 4.99% unless increased to 9.99% per the agreement.
Azitra, Inc. filed a Form 8-K reporting a corporate charter change: a Certificate of Amendment was filed with the Delaware Secretary of State on August 20, 2025. The 8-K includes standard filing checkboxes but provides no further detail about the amendment's text, purpose, or effect on capital structure, governance, equity classes, or shareholder rights. No financial tables, earnings data, or transaction details are included in the disclosed excerpt.
L1 Capital Global Opportunities Master Fund, Ltd. filed an amended Schedule 13G reporting beneficial ownership of 1,521,492 shares of Azitra, Inc. Class A common stock, representing 6.48% of the outstanding common shares. The filing states these shares represent common stock underlying 1,521,492 warrants purchased July 24, 2024, and the percentage is calculated using 23,476,354 shares outstanding as of August 11, 2025.
The reporting person is organized in the Cayman Islands and discloses sole voting and dispositive power over the 1,521,492 shares. Directors David Feldman and Joel Arber are identified as directors of the reporting fund; the filing includes customary disclaimers about their beneficial ownership limited to pecuniary interests. The amendment emphasizes the holdings were not acquired to influence control of the issuer.